How Luxury Yacht Owners Are Designing Vessels Around Health and Wellness - Robb Report

Rethink trial design with decentralized, community-based models to cut barriers, let patients enroll closer to home, and preserve high-quality safety data. Making clinical trials more accessible requires rethinking how studies are designed, supported, and conducted, particularly for patients receiving care in community settings. In an interview with Targeted Oncology, Krish Patel, MD, executive director of hematologic cancer research at Sarah Cannon Research Institute, discusses the role of trial sponsors, research organizations, community oncology sites, and regulatory agencies in reducing barriers to participation. Patel emphasizes that while community oncology sites may have varying capabilities, they care for a large proportion of patients who could benefit from clinical trial participation. He argues that stakeholders should reassess which traditional trial requirements are truly necessary to determine whether a therapy is safe and effective and which may create unnecessary barriers for patients and sites. One potential solution is greater use of decentralized trial models.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.